Valuation: Ovid Therapeutics Inc.

Market Cap 46Cr 40Cr 37Cr 34Cr 64Cr 4.42TCr 66Cr 442.09Cr 173.46Cr 2.16TCr 172.42Cr 168.64Cr 7.44TCr P/E 2026 *
-5.09x
P/E 2027 * -4.61x
Enterprise Value 46Cr 40Cr 37Cr 34Cr 64Cr 4.42TCr 66Cr 442.09Cr 173.46Cr 2.16TCr 172.42Cr 168.64Cr 7.44TCr EV / Sales 2026 *
4,271x
EV / Sales 2027 * 2,755x
Free-Float
92.96%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+2.44%
1 week-7.69%
Current month-6.32%
1 month+11.50%
3 months-8.70%
6 months+58.49%
Current year+54.60%
1 week 2.37
Extreme 2.37
2.82
1 month 2.19
Extreme 2.19
2.84
Current year 1.36
Extreme 1.36
3.1
1 year 0.36
Extreme 0.36
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07Free

Chief Financial Officer

50,000 0.0268%
06/07Other

Chief Financial Officer

4,50,625 0.2414%
15/06Free

Director

1,30,000 0.0697%
Change 5-day change 1-year change 3-year change Capi.($)
+2.44%-7.69%+584.78%-28.41% 46Cr
-1.39%-6.15%+56.05%+71.53% 5.45TCr
+3.13%+11.16%+67.30%+94.35% 5.59TCr
-0.64%-5.89%+6.61%+429.81% 2.39TCr
+1.70%-1.67%-16.88%-14.22% 2.29TCr
+3.51%+7.50%+47.81%-3.33% 2TCr
+1.94%+0.21%+39.31%-29.41% 1.75TCr
+10.00%-2.06%+210.10%+370.99% 1.54TCr
+7.69%+4.38%+56.51%+712.88% 1.52TCr
-0.91%-0.95%+26.13%+189.60% 1.4TCr
Average +2.75%-0.78%+107.77%+179.38% 2.4TCr
Weighted average by Cap. +2.03%+0.45%+54.07%+157.34%

Financials

2026 *2027 *
Net sales 1L 93.99T 86.7T 79.7T 2L 1.03Cr 2L 10.35L 4L 50.56L 4L 4L 1.74Cr 2L 1L 1L 1L 2L 1.6Cr 2L 16.05L 6L 78.39L 6L 6L 2.7Cr
Net income -7.71Cr -6.74Cr -6.22Cr -5.72Cr -11Cr -742.07Cr -11Cr -74Cr -29Cr -362.71Cr -29Cr -28Cr -1.25TCr -8.98Cr -7.85Cr -7.25Cr -6.66Cr -13Cr -864.46Cr -13Cr -87Cr -34Cr -422.52Cr -34Cr -33Cr -1.46TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
16/26/16 $2.520 +2.44% 8,68,780
14/26/14 $2.460 +1.23% 12,77,928
13/26/13 $2.430 -3.57% 11,47,843
10/26/10 $2.520 -3.08% 13,94,301
09/26/09 $2.600 -4.76% 18,60,058
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.460USD
Average target price
5.471USD
Spread / Average Target
+122.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock